Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GMP manufacturing of cell and gene therapy products: Challenges, opportunities, and pathways forward

25 Feb 2025

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40010336
DOI: 10.1016/j.ymthe.2025.02.022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GMP manufacturing of cell and gene therapy products: Challenges, opportunities, and pathways forwardPMID 40010336Read ↗

Manufacturing Cell and Gene Therapies: Challenges in Clinical TranslationSemantic proximity Read ↗

Considerations for manufacturing of cell and gene medicines for clinical developmentSemantic proximity Read ↗

Toward precision manufacturing of immunogene T-cell therapiesSemantic proximity Read ↗

Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and AccessibilitySemantic proximity Read ↗

Towards a commercial process for the manufacture of genetically modified T cells for therapySemantic proximity Read ↗

Gene therapy: challenges in cell culture scale-upSemantic proximity Read ↗

Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory GuidelinesSemantic proximity Read ↗

Status and future developments for downstream processing of biological products Perspectives from the Recovery XIX yield roundtable discussionsSemantic proximity Read ↗

Manufacturing of viral vectors for gene therapy: part I. Upstream processingSemantic proximity Read ↗

Driving adoption of new technologies in biopharmaceutical manufacturingSemantic proximity Read ↗

Towards automated manufacturing of clinical scale gene-modified T cellsSemantic proximity Read ↗

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.